Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The US Food and Drug Administration approved sorafenib in human patients with liver, thyroid, or renal carcinoma. The aim of this study was to help guide future pharmacokinetic (PK) studies of sorafenib...

Descripción completa

Detalles Bibliográficos
Autores principales: Foskett, Amanda, Manley, Christina, Naramore, Rebecca, Gordon, Ira K, Stewart, Bridget M, Khanna, Chand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042486/
https://www.ncbi.nlm.nih.gov/pubmed/30050861
http://dx.doi.org/10.2147/VMRR.S149678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042486/
https://www.ncbi.nlm.nih.gov/pubmed/30050861
http://dx.doi.org/10.2147/VMRR.S149678

Ejemplares similares